Changes of Lipid Proffie and C-Reactive Protein after Withdrawal of Xuezhikang, an Extract of Cholestin, in Patients With Stable Angina Pectoris

Objectives In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein （CRP） resulting in reduction of cardiovascular events. However, information about discontinuation of statin therapy in stable cardiac patients is limited. This was a prospective cohort study to explore whether withdrawal of statin treatment could result in rebound of inflammation in patients with stable angina pectofis in a short-term course. Methods and Results 75 patients with stable angina pectoris were randomly divided into three groups： ① Pretreatment with Xuezhikang （XZK, an extract of cholestin） for 6 weeks and then replaced by placebo; ②Treatment with XZK throughout the study; ③ Placebo. Lipid levels, highly sensitive CRP （hs-CRP） and serum cardiac troponin T （cTnT） were assessed before receiving the XZK therapy, 1 day before discontinuation of XZK, and on day 1, 2, 3, 7 and 14 after discontinuation of XZK, respectively. At day 14 after discontinuation of XZK therapy, total cholesterol, LDL-C and triglyceride significantly increased, whereas HDL-C level significantly decreased. The median level of hs-CRP increased significantly from the second day after withdrawal of XZK therapy. There was a prominent rebound of hs-CRP concentration 3 days after discontinuation of XZK therapy. 7 to 14 days after discontinuation of XZK therapy, the hs-CRP concentration declined to a similar level as in the placebo group. Elevated eTnT level did not occur throughout the study course in either guroup Conclusios Short-term discontinuation of statin therapy could induce a rapid rebound phenomenon of inflammatory response independently of changes of lipid parameters. However, it was not enough to induce myocardial injury in this cohort of patients with stable angina peetoris.     

Effects of Withdrawal of Xuezhikang, an Extract of Cholestin, on Lipid Profile and C-reactive Protein: A Short-Term Time Course Study in Patients with Coronary Artery Disease

Objective C-reactive protein (CRP) is considered a risk factor for coronary artery disease. In addition to its lipid-lowering properties, statin decreases the level of CRP. Abrupt cessation of statin therapy during treatment could increase CRP level independently of the elevation of serum lipids and the incidence of cardiac events in patients with atherosclerotic heart disease. Xuezhikang (XZK), an extract of cholestin, has a marked modulating effect on lipid and CRP concentrations in different study time course. However, no attention has been paid to the changes of lipid profile and CRP concentrations after withdrawal of XZK treatment. This study was designed to explore short-term time course effects on lipid profile and CRP concentrations after withdrawal of XZK treatment in coronary heart disease patients. Materials and methods Seventy-five consecutive patients with documented coronary heart disease were randomly divided into three groups: 1. Pretreatment with XZK 1,200 mg daily for 6 weeks and then replaced by placebo (XZK discontinued group; n = 25); 2. Treatment with XZK 1,200 mg daily throughout the study (XZK continued group; n = 25); or 3. Placebo (no XZK group; n = 25). Lipid levels (total cholesterol, HDL-C, LDL-C and triglycerides) and CRP were assessed before receiving the XZK therapy, 1 day before discontinuation of XZK, and on days 1, 2, 3, 7 and 14 after discontinuation of XZK, respectively. Results After 6-week XZK treatment, the fasting total cholesterol, LDL-C, triglyceride and median hs-CRP concentrations decreased, whereas HDL-C concentration increased significantly (p < 0.001, respectively). At day 14 after discontinuation of XZK therapy, total cholesterol (15%), LDL-C (17%) and triglyceride (20%) significantly increased (p < 0.001, respectively), whereas HDL-C level (15%) significantly decreased (p < 0.05). The median level of CRP increased by 11, 65, 128, 103 and 101% on the first, second, third, seventh, and fourteenth day after withdrawal of XZK therapy (p > 0.05, <0.05, <0.001, <0.001, <0.001, compared with 1 day before withdrawal of XZK therapy, respectively). There was a prominent rebound of CRP concentration 3 days after discontinuation of XZK therapy. At this time point, hs-CRP concentration was higher than in the placebo group (p < 0.05). Seven to 14 days after discontinuation of XZK therapy, the hs-CRP concentration declined to a similar level as in the placebo group. No significant correlation was seen between the changes in hs-CRP and lipid profile at all time points. Conclusions The level of hs-CRP increases on the second day after withdrawal of XZK and there is a prominent rebound 3 days after discontinuation of XZK therapy. The increase of CRP ends within 7 days, where lipids increase at 14 days after discontinuation of XZK therapy. The results may be clinically important for patients with coronary artery disease.     

不稳定性心绞痛患者C-反应蛋白与肌钙蛋白T的变化

目的探讨不稳定性心绞痛患者血清C-反应蛋白(CRP)及肌钙蛋白T(TnT)的变化.方法选择92例不稳定性心绞痛患者(实验组),28例稳定性心绞痛患者(对照组),分别取血测定CRP和TnT.结果实验组中TnT为阳性30例(32.6%),TnT为阴性62例(67.4%);对照组则均为阴性.实验组TnT阳性患者的CRP显著高于TnT阴性患者及对照组,有非常显著性差异(P＜0.001).结论实验组约1/3可出现TnT升高,其CRP亦显著高于TnT阴性的患者,且CRP与TnT呈正的直线相关(γ=0.489,P＜0.01).     

血浆C-反应蛋白与行支架植入术后的稳定性心绞痛患者预后的关系

目的 C-反应蛋白(CRP)预测支架植入术后非靶血管病变的进展和靶病变的再狭窄。方法测定311例慢性稳定性心绞痛患者入院时及随访时的血浆CRP浓度。所有患者经皮冠状动脉支架植入术,并于6-9个月后行冠状动脉造影随访。结果进展组患者高敏CRP浓度高于非进展组患者[1.60(0.80-3.46)mg/lvs0.96(0.55-1.87)mg/l,P<0.001]。再狭窄组患者高敏CRP浓度高于非再狭窄组患者[1.46(0.90-2.90)mg/lvs1.15(0.59-2.34)mg/l,P=0.026]。多因素回归分析显示入院时血浆CRP是非靶血管病变狭窄快速进展的独立预测因子(OR=1.207,95%CI1.073-1.357,P=0.002)。结论血浆CRP可独立预测稳定性心绞痛患者支架植入术后非靶血管病变狭窄的快速进展,但与靶病变再狭窄无关。     

心绞痛患者血清超敏C-反应蛋白的表达及其临床意义

目的探讨不同类型心绞痛患者血清超敏C-反应蛋白(Hs-CRP)的表达及其临床意义。方法将76例冠心病心绞痛患者分为不稳定型心绞痛组(n=41)和稳定型心绞痛组(n=35),于入院后24h内抽血测定患者的血清Hs-CRP浓度,比较两组患者血清Hs-CRP浓度的差异。结果不稳定型心绞痛组患者血清Hs-CRP浓度显著高于稳定型心绞痛组(P<0·05)。结论不稳定心绞痛的发生与急性炎症反应有关,Hs-CRP对判断心绞痛患者的病情及预后有指导意义。     

注射用血塞通对不稳定型心绞痛疗效及血清C反应蛋白的影响

目的观察注射用血塞通治疗不稳定型心绞痛的临床疗效及对血清C反应蛋白(CRP)的影响。方法将不稳定型心绞痛患者40例随机分为两组。对照组20例予硝酸酯类、美托洛尔、阿司匹林、阿托伐他汀等治疗。治疗组20例在对照组治疗基础上加用注射用血塞通400mg,加入5%葡萄糖注射液250mL中静脉输注,每日1次,2周1个疗程。结果两组症状比较,治疗组总效率90%,对照组总有效率65%。两组心电图(ECG)疗效比较,治疗组总效率90%,对照组总有效率60%,差异有统计学意义(P<0.05)。两组CRP治疗后与治疗前相比,组内及组间比较差异均有统计学意义(P<0.05)。结论常规疗法联合注射用血塞通对不稳定型心绞痛具有良好的疗效。     

C反应蛋白与肌钙蛋白测定对于不稳定性心绞痛的诊断价值

目的:观察不稳定性心绞痛(UAP)与C反应蛋白(CRP)、肌钙蛋白(cTnT)的关系。方法;测定38例UAP患者(UAP组),35例稳定性心绞痛患者(SAP组)及32例健康对照组的CRP、cTnT和血脂水平,并进行比较,测定比较UAP组治疗前、后的CRP、cTnT水平。结果;UAP组与SAP组、对照组比较,其CRP、cTnT水平显著升高(P<0.05～0.01);UAP组的CRP、cTnT阳性率分别是42.8％、28.5％,两者比较有显著差异(P<0.05)。UAP组、SAP组血脂水平无显著差异(P>0.05),而与对照组相比均有显著差异(P<0.05);UAP组治疗后CRP、cTnT值显著下降(P分别<0.05,<0.01)。结论:UAP的触发因素可能与感染有关,CRP在UAP诊断中的敏感性比cTnT的高。动态观察CRP及cTnT有助于UAP疗效、预后的判断。     

微血管性心绞痛患者高敏C反应蛋白、可溶性细胞分化抗原40配体检测的临床意义

目的:评价微血管性心绞痛患者高敏C反应蛋白(hsCRP)、可溶性细胞分化抗原40配体(sCD40L)水平的临床意义.方法:入选微血管性心绞痛组患者98例,冠心病组患者50例,正常对照组50例,用乳胶增强免疫比浊法检测3组患者血清hsCRP浓度,用酶联免疫吸附法检测3组患者血清sCD40L的浓度.结果:微血管性心绞痛组血清hsCRP和sCD40L浓度均高于正常对照组(P<0.05),而微血管性心绞痛组血清hsCRP和sCD40L浓度均低于冠心病组(P<0.05),差异均有统计学意义.结论:微血管性心绞痛患者心肌缺血与炎症反应有关.     

Effects of XUEZHIKANG on Oxidized Low Density Lipoprotein,C-Reactive Protein, Fibrinogen in Unstable Angina Pectoris Patients

Objectives To study the effects of XUEZHIKANG on lipid modulating and the level of oxidized low density lipoprotein(OX -LDL),C-reactive protein(CRP), fibrinogen(FIB) in serum.Methods XUEZHIKANG was given to patients with unstable angina pectoris and hyperlipidemia at a dose of 0. 6 gram bid for 2 months and with half-dose for another 2 months. Vitamin E was given to unstable angina pectoris patients with normal lipid at the dose of 0. 1 gram bid for 4 months respectively.Then compared the level of lipid and OX - LDfL, CRP,FIB in serum at beginning, first- month and second-month. Results XUEZHIKANG can reduce the serum level of total cholesterol, low density lipoprotein in 1 month, and gained better effect in 2 months. It can also reduce triglyceride and increase high density lipoprotein in 2 months. Compared with vitamin EXUEZHIKANG can reduce the level of OX- LDL,CRP, FIB significantly after treatment for 2 months.Conclusions XUEZHIKANG has significant effect in lipid modulating , and it can also inhibit the development of inflammation in coronary plaque.     

早期瑞舒伐他汀干预对不稳定型心绞痛支架术后血清妊娠相关蛋白A和高敏C反应蛋白的影响

目的 探讨瑞舒伐他汀对血脂水平正常的不稳定型心绞痛患者行PCI术后妊娠相关蛋白A(PAPP-A)及高敏C反应蛋白(hs-CRP)的影响.方法 56例血脂水平正常的不稳定型心绞痛患者,随机分为瑞舒伐他汀组和常规治疗组,两组患者分别于PCI术前、术后24 h、术后1个月检测血清PAPP-A 和hs-CRP水平.结果 两组患者术后24 h与术前比较,血清PAPP-A和hs-CRP浓度均有明显升高,但两组间比较,无明显差异;术后1个月,两组血清PAPP-A 和hs-CRP水平与术后24 h比较,均有回降,但瑞舒伐他汀组较常规治疗组回降更为明显,两者存在统计学意义(P<0.05).结论 早期使用瑞舒伐他汀能更有效降低不稳定型心绞痛患者PCI术后PAPP-A和hs-CRP水平.     

戒烟时间对稳定型心绞痛患者血浆高敏C反应蛋白及丙二醛浓度的影响

分析稳定型心绞痛患者戒烟时间对血浆高敏C反应蛋白及丙二醛浓度的影响。将 10 1例稳定型心绞痛患者根据吸烟情况分为吸烟组、不吸烟组及戒烟组 ,其中戒烟组又根据戒烟时间长短分为近期戒烟组和长期戒烟组。分别用颗粒增强超敏透射比浊法和硫代巴比妥酸法测定血浆高敏C反应蛋白及丙二醛浓度。结果发现 ,吸烟组血浆高敏C反应蛋白及丙二醛浓度较不吸烟组明显升高 (分别为 4 .82± 0 .37mg L比 1.74± 0 .31mg L和 1.0 8± 0 .31mmol L比 0 .86± 0 .2 0mmol L ,P均 <0 .0 1) ;长期戒烟组血浆高敏C反应蛋白浓度与近期戒烟组相比明显降低 (1.91± 0 .2 6mg L比 4 .6 6± 0 .2 4mg L ,P <0 .0 1) ;但丙二醛浓度在两组间无显著性差异 (0 .93± 0 .17mmol L比 0 .95± 0 .14mmol L ,P >0 .0 5 )。结果提示 ,吸烟对氧化应激及炎症介质均有影响 ,但对两者的作用时间长短可能不一致。     

辛伐他汀调脂治疗对血脂正常的稳定性心绞痛患者心肌缺血的影响

目的探讨辛伐他汀调脂治疗对血脂正常的稳定性心绞病患者心肌缺血的影响。方法64例血脂正常且心电图运动试验阳性的稳定,挂心绞痛患者随机分为辛伐他汀组（治疗组）和对照组,治疗组除给予常规治疗外,同时口服辛伐他汀20mg每天一次调脂治疗,对照组仅给予常规治疗。于治疗前、治疗后6个月时分别行24h动态心电图、心电图运动试验检测心肌缺血总负荷（total ischemic burden,TIB）及运动诱发的心肌缺血,并记录缺血相关事件。结果治疗后6个月治疗组TIB低于对照组TIB（P〈0．05）。治疗组运动耐量增加,由运动诱发的心肌缺血低于对照组（P〈0．05）。治疗组的缺血相关事件明显少于对照组（P〈0．05）。结论辛伐他汀调脂治疗对血脂正常的稳定性心绞痛患者具有抗心肌缺血作用,并能减少运动诱发的心肌缺血以及缺血相关事件的发生。     

不同糖耐量水平稳定型心绞痛患者高敏C反应蛋白水平与内皮功能的相关性

目的观察不同糖耐量水平稳定型心绞痛患者高敏C反应蛋白、可溶性细胞间黏附分子1和可溶性血管细胞黏附分子1水平及肱动脉内皮功能,同时分析患者高敏C反应蛋白水平与可溶性细胞间黏附分子1水平、可溶性血管细胞黏附分子1水平及肱动脉内皮功能之间的相关性。方法选取60例经冠状动脉造影证实为稳定型心绞痛患者,根据口服葡萄糖耐量试验分为糖耐量正常组、糖耐量减退组和2型糖尿病组,每组20例患者。采用酶联免疫吸附法检测不同糖耐量水平稳定型心绞痛患者血清高敏C反应蛋白、可溶性细胞间黏附分子1和可溶性血管细胞黏附分子1水平。同时采用超声心动图检测不同糖耐量水平稳定型心绞痛患者肱动脉内皮依赖性血流量介导的扩张反应。结果糖耐量正常组、糖耐量减退组和2型糖尿病组血清高敏C反应蛋白水平分别为1.03±0.32 mg/L、2.14±0.82 mg/L及3.05±1.56 mg/L,其中糖耐量正常组和2型糖尿病组比较有统计学差异(P<0.05)。糖耐量正常组、糖耐量减退组和2型糖尿病组血清可溶性细胞间黏附分子1水平分别为112.76±32.03μg/L、175.37±41.21μg/L及234.21±56.14μg/L;可溶性血管细胞黏附分子1水...     

银丹心脑通软胶囊对不稳定型心绞痛患者血脂及超敏C-反应蛋白的影响

目的观察银丹心脑通软胶囊对不稳定型心绞痛患者血脂、超敏C-反应蛋白(hs-CRP)的影响。探讨银丹心脑通软胶囊治疗不稳定型心绞痛的可能机制。方法 402例冠心病不稳定型心绞痛患者,随机分为银丹心脑通软胶囊组(治疗组)与常规治疗组(对照组)。治疗组在常规治疗基础上加服银丹心脑通软胶囊4粒,每日3次口服。分别于治疗前及治疗3个月测定两组血清胆固醇(TC)、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)、hs-CRP浓度,并与对照组比较。结果两组治疗3个月后,观察疗效。治疗组显效率及有效率比对照组更高(P<0.05);并测得两组TC、LDL、hs-CRP分别低于治疗前水平,HDL则较治疗前升高(P<0.05)。治疗组上述参数变化与对照组比较有统计学意义(P<0.05)。结论银丹心脑通软胶囊可能通过调脂、抗炎等机制治疗冠心病不稳定型心绞痛。     

卡维地洛对不稳定性心绞痛患者血管内皮功能及炎症标志物的影响

目的:观察卡维地洛对不稳定性心绞痛患者血管内皮功能及炎症标志物的影响。方法:采用随机、对照和单盲方法将86例不稳定性心绞痛患者分为常规治疗组(n=43)和卡维地洛组(n=43)。疗程均为4周。治疗过程中有6例被剔除,其中常规治疗组4例,卡维地洛组2例。正常组(20例)不予任何治疗。治疗前后分别采用高分辨率血管超声检测肱动脉血流介导性舒张功能变化,测定血中高敏C反应蛋白(hsCRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)含量。结果:①不稳定性心绞痛患者肱动脉血流介导性舒张功能较正常人明显减弱[(5.8±2.7)%比(13.8±3.6)%,P＜0.001],hS-CRP、TNF-α及IL-6水平明显高于正常组(P均＜0.01)。②常规治疗组和卡维地洛组治疗前肱动脉血流介导性舒张功能无显著差异。治疗后卡维地洛组肱动脉血流介导性舒张功能明显增强,与治疗前比较有非常显著性差异[(5.7±2.1)%比(8.6±1.8)%,P＜0.001],而常规治疗组治疗前后无明显变化。治疗后肱动脉血流介导性舒张功能增强与hsCRP、TNF-α、IL-6含量减少具有明显相关性(r=-0.68、-0.62、-0.65,P均＜0.01)。③卡维地洛治疗后血中hsCRP、TNF-α、IL-6含量均显著降低(P均＜0.01),而常规治疗前后则无明显差异(P均＞0.05)。结论:不稳定性心绞痛患者的血管内皮损伤与炎症具有密切关系。卡维地洛对不稳定性心绞痛患者具有明显的改善内皮功能作用和抗炎效应。抗炎作用可能是卡维地洛重要的药理作用之一。     

Effects of Amlodipine and Isosorbide Dinitrate on Exercise-Induced and Ambulatory Ischemia in Patients with Chronic Stable Angina Pectoris

This study was designed to compare once-daily administration of 5–10 mg amlodipine with two daily doses of 40 mg sustained-release isosorbide dinitrate in 59 patients with stable angina using a randomized, double-blind, crossover study design. Anginal episodes, nitroglycerin consumption, and possible adverse events were recorded in a diary. A maximal symptom-limited bicycle exercise test and 48-hour ambulatory ECG monitoring were performed at baseline and at the end of each 5-week period of therapy. Exercise time, time to angina, time to ST depression, and maximal ST depression were measured during exercise. During ambulatory monitoring, the number of ischemic episodes and the duration per hour of ST depression were assessed. Amlodipine significantly reduced anginal episodes (P < 0.001) when compared with isosorbide dinitrate. Furthermore, amlodipine prolonged time to ST depression (P < 0.001) and time to angina (P < 0.05) when compared with isosorbide dinitrate. The number and duration of ischemic episodes during ambulatory monitoring were significantly reduced with amlodipine when compared with baseline values (P < 0.05), whereas no differences were found between isosorbide dinitrate and baseline. Adverse events were reported more frequently with isosorbide dinitrate than with amlodipine (P < 0.02). Amlodipine appears to be more effective and tolerable than sustained-release isosorbide dinitrate as monotherapy for chronic stable angina. This revised version was published online in July 2006 with corrections to the Cover Date.     

切割球囊血管成形术对不稳定性心绞痛患者血管性假血友病因子、白细胞介素-6和C-反应蛋白的影响

目的 :比较切割球囊血管成形术与普通球囊血管成形术对不稳定性心绞痛患者血浆血管性假血友病因子 (vWF)和血清白细胞介素 6(IL 6)、C 反应蛋白 (CRP)浓度的影响。方法 :选择 65例拟行冠状动脉 (冠脉 )介入治疗的不稳定性心绞痛患者 ,随机分为两组 ,分别接受切割球囊血管成形术 (切割球囊组 )或普通球囊血管成形术 (普通球囊组 ) ,球囊扩张后均放置支架。分别于术前、术后即刻、术后 2h和 6h抽取冠状静脉窦血样测定血浆血管性假血友病因子和血清IL 6的浓度 ;另于术前、术后 6h、术后 2 4h和 48h抽取肘静脉血样 ,测定血清CRP的浓度。以上指标均以酶联免疫吸附法进行测量。结果 :普通球囊组血浆血管性假血友病因子浓度术后即刻和术后 2h ;血清IL 6浓度术后即刻 ,术后 2h和 6h以及血清CRP浓度术后 6h、2 4h和 48h都明显高于切割球囊组 ,有显著性差异 (P均 <0 0 5～ 0 0 1)。结论 :单纯切割球囊血管成形术对不稳定性心绞痛患者血浆血管性假血友病因子、血清IL 6和CRP浓度的影响均小于单纯普通球囊血管成形术 ,联合支架置入术后有相似结果 ,这可能是前者通过减轻对炎症反应的影响 ,减少再狭窄及心血管事件发生的机制之一。     

速效救心丸干预对稳定型心绞痛介入治疗患者围术期心肌保护作用的研究

目的探讨速效救心丸对稳定型心绞痛患者（SA）经皮冠状动脉介入术（PCI）效果的影响,观察其围术期的心肌保护作用。方法60例行冠状动脉造影检查并行PCI术的气滞血瘀型稳定型心绞痛患者,随机分为速效救心丸治疗组30例（治疗组）和单用西药对照组30例（对照组）,观察速效救心丸干预对稳定型心绞痛患者支架植入术前后血液心肌酶、冠脉血流以及围术期心肌梗死发生率的影响。结果PCI术前心肌梗死溶栓（TIMI）血流分级达到3级者,治疗组26例,对照组20例,两组比较差异无统计学意义（P〉0．05）;术后TIMI血流3级者,治疗组30例,对照组26例,两组比较差异无统计学意义（P〉0．05）,治疗组PCI术后冠脉血流改善有优于对照组的趋势。两组均可以降低稳定型心绞痛患者择期PCI术围术期心肌酶水平,两组术后24h血肌钙蛋白（TnI）浓度差异有统计学意义（P〈0．05）;治疗组围术期心肌损伤与心肌梗死的发生率明显低于对照组（P〈0．05）。结论与单纯西药治疗相比,速效救心丸治疗有改善稳定型心绞痛患者支架植入后的冠脉血流灌注的趋势,且可降低稳定型心绞痛患者PCI围术期血心肌酶水平,减少围术期心肌梗死的发生率。     

Comparison of Men Versus Women in Cross-Sectional Area Luminal Narrowing, Quantity of Plaque, Presence of Calcium in Plaque, and Lumen Location in Coronary Arteries by Intravascular Ultrasound in Patients with Stable Angina Pectoris

Women have an increased mortality after coronary interventions compared with men, which may be partly explained by differences in comorbid clinical conditions. However, whether women also have quantitative differences in coronary atherosclerosis is not known. Preinterventional intravascular ultrasound (IVUS) was used to study de novo, nonostial native coronary lesions in 169 women and 549 men with chronic angina. The external elastic membrane (EEM), lumen, and plaque + media (P + M) areas, plaque burden, plaque eccentricity, and calcium were measured at the target lesion and at a proximal reference site. All cross-sectional IVUS measures were also corrected for body surface area. Results are reported as mean ± 1 SD. Women had significantly smaller reference site EEM (16.5 ± 5.3 vs 19.4 ± 6.3 mm², p <0.0001), lumen (8.7 ± 3.0 vs 9.9 ± 4.0 mm², p = 0.0020), and P + M areas (7.8 ± 3.7 vs 9.5 ± 4.2 mm², p = 0.0001). Women also had significantly smaller lesion site EEM (16.2 ± 5.9 vs 18.3 ± 6.7 mm², p = 0.0028), lumen (2.4 ± 1.7 vs 2.9 ± 2.6 mm², p = 0.0273), and P + M areas (13.6 ± 5.7 vs 15.3 ± 6.4 mm², p = 0.0112). However, when corrected for BSA, these differences were no longer significant. Women and men also had similar reference and lesion plaque burden, eccentricity, and calcium. Preinterventional IVUS analysis failed to detect any quantitative or qualitative differences in coronary atherosclerosis in men compared with women.

To determine whether there are quantitative differences in coronary atherosclerosis in men compared with women, preinterventional intravascular ultrasound (IVUS) was used to study de novo, nonostial native vessel lesions in 169 women and 549 men with chronic angina. Women had significantly smaller reference segment and target lesion external elastic membrane, lumen, and plaque cross-sectional areas; however, when corrected for body surface area, these differences were no longer significant. Women and men also had similar reference segment and target lesion plaque burden, eccentricity, and calcification. Preinterventional IVUS analysis failed to detect any quantitative differences in coronary atherosclerosis in men compared with women.     

老年人血清sICAM-1、sVAP-1、CRP与心脑血管疾病相关性的临床研究

目的探讨老年心脑血管病患者可溶性细胞间粘附分子-l(sICAM-1)、可溶性血管粘附蛋白-l(sVAP-1)及C反应蛋白(CRP)变化及其与疾病的相关性。方法随机选择老年稳定性心绞痛患者、脑梗死患者及老年健康体检者63例,分为3组,每组21例。分别检测其血清sVAP-1s、ICAM-1、CRP水平并进行组间比较分析。结果稳定性心绞痛组、脑梗死组sICAM-1值显著高于正常对照组,稳定性心绞痛组sVAP-1值显著高于另外二组,但脑梗死组与正常对照组间无差异;稳定性心绞痛组、脑梗死组CRP值较正常对照组高,其组间差异具有显著性。同组内三项指标相关分析显示:除稳定性心绞痛组sICAM-1与sVAP-1相关外,其它组内各指标间未见显著相关性。结论sICAM-1、sVAP-1、CRP在老年心脑血管疾病患者体内表达均较正常老年人高,三项指标与组织缺血程度、炎症坏死的严重程度有一定的相关性,可作为临床上老年心脑血管疾病诊断、治疗及预后的依据。